Related references
Note: Only part of the references are listed.Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission
A. Ruggeri et al.
BONE MARROW TRANSPLANTATION (2016)
Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS
J. De La Serna et al.
BONE MARROW TRANSPLANTATION (2016)
Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial
Irwin Walker et al.
LANCET ONCOLOGY (2016)
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Nicolaus Kroeger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
Young Sok Ji et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2016)
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
Sally Arai et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants
J. R. Passweg et al.
BONE MARROW TRANSPLANTATION (2015)
Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation
L. Binkert et al.
BONE MARROW TRANSPLANTATION (2015)
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Marie Therese Rubio et al.
HAEMATOLOGICA (2015)
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial
Alessandro Rambaldi et al.
LANCET ONCOLOGY (2015)
The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Marie Therese Rubio et al.
HAEMATOLOGICA (2015)
Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
F. Baron et al.
BONE MARROW TRANSPLANTATION (2014)
Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases
Roberto Crocchiolo et al.
CANCER (2013)
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
Hui Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT
R. Devillier et al.
BONE MARROW TRANSPLANTATION (2012)
Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
Claudio Anasetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life
Gheath Alatrash et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire
M. Mohty et al.
LEUKEMIA (2010)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Juergen Finke et al.
LANCET ONCOLOGY (2009)
Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
Borje S. Andersson et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2
Y. S. Chae et al.
BONE MARROW TRANSPLANTATION (2007)
Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: A matched pair analysis
James A. Russell et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: Long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation
A Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
A Shimoni et al.
LEUKEMIA (2006)
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: An individual patient data meta-analysis of nine randomized trials
M al-Jurf et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
M de Lima et al.
BLOOD (2004)
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen
M Mohty et al.
BLOOD (2003)
Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
A Bacigalupo et al.
BLOOD (2001)
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
WI Bensinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
